Arrowhead Pharmaceuticals Inc
ARWR29.075USD
+1.075+3.84%
Cierre 09/05, 16:00（ET）Cotizaciones retrasadas 15 min
4.02BCap. mercado
PérdidaP/E TTM
Más Datos de Arrowhead Pharmaceuticals Inc Compañía
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Información de la empresa
Símbolo de cotizaciónARWR
Nombre de la empresaArrowhead Pharmaceuticals Inc
Fecha de salida a bolsaDec 14, 1993
Director ejecutivoDr. Christopher Richard (Chris) Anzalone, Ph.D.
Número de empleados609
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 14
Dirección177 E Colorado Blvd
CiudadPASADENA
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal91105
Teléfono16266964702
Sitio Webhttps://arrowheadpharma.com/
Símbolo de cotizaciónARWR
Fecha de salida a bolsaDec 14, 1993
Director ejecutivoDr. Christopher Richard (Chris) Anzalone, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
Ms. Victoria (Vicki) Vakiener
Ms. Victoria (Vicki) Vakiener
Independent Director
Independent Director
37.94K
+0.01%
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
35.78K
-2.60%
Mr. Daniel Apel
Mr. Daniel Apel
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Vincent Anzalone
Mr. Vincent Anzalone
Investor Relations
Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 17 de ago
Actualizado: dom., 17 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
12.73%
The Vanguard Group, Inc.
11.21%
Avoro Capital Advisors LLC
7.67%
State Street Global Advisors (US)
4.61%
Slate Path Capital LP
3.78%
Otro
60.00%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
12.73%
The Vanguard Group, Inc.
11.21%
Avoro Capital Advisors LLC
7.67%
State Street Global Advisors (US)
4.61%
Slate Path Capital LP
3.78%
Otro
60.00%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
41.14%
Investment Advisor/Hedge Fund
23.06%
Hedge Fund
7.19%
Individual Investor
4.44%
Research Firm
2.60%
Sovereign Wealth Fund
1.39%
Bank and Trust
0.96%
Pension Fund
0.95%
Venture Capital
0.18%
Otro
18.08%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
583
126.42M
91.54%
+6.47M
2025Q1
603
125.23M
90.71%
+6.54M
2024Q4
609
108.09M
85.81%
-8.58M
2024Q3
605
106.83M
85.95%
-7.44M
2024Q2
608
107.20M
86.35%
-5.57M
2024Q1
621
105.82M
85.63%
+13.72M
2023Q4
625
87.51M
81.46%
-1.31M
2023Q3
624
83.79M
78.09%
-822.40K
2023Q2
641
80.82M
75.59%
-4.71M
2023Q1
648
81.64M
75.46%
-182.63K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
18.18M
13.17%
+3.66M
+25.22%
Mar 31, 2025
The Vanguard Group, Inc.
13.18M
9.54%
+1.02M
+8.37%
Mar 31, 2025
Avoro Capital Advisors LLC
11.11M
8.05%
--
--
Mar 31, 2025
State Street Global Advisors (US)
7.00M
5.07%
+983.02K
+16.34%
Mar 31, 2025
Slate Path Capital LP
5.23M
3.79%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
3.32M
2.4%
-1.74M
-34.40%
Mar 31, 2025
Anzalone (Christopher Richard)
3.92M
2.84%
-141.12K
-3.47%
Apr 11, 2025
Geode Capital Management, L.L.C.
2.95M
2.14%
-4.63K
-0.16%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.67M
1.93%
-231.80K
-7.99%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de sep
Actualizado: mar., 2 de sep
Nombre
Proporción
Invesco Biotechnology & Genome ETF
2.8%
Global X Genomics & Biotechnology ETF
2.22%
ROBO Global Healthcare Technology & Innovation ETF
1.58%
Invesco S&P SmallCap Health Care ETF
1.34%
ALPS Medical Breakthroughs ETF
1.31%
Virtus LifeSci Biotech Clinical Trials ETF
1.15%
Tema Heart & Health ETF
1.02%
SPDR S&P Biotech ETF
0.56%
WisdomTree BioRevolution Fund
0.45%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Ver más
Invesco Biotechnology & Genome ETF
Proporción2.8%
Global X Genomics & Biotechnology ETF
Proporción2.22%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.58%
Invesco S&P SmallCap Health Care ETF
Proporción1.34%
ALPS Medical Breakthroughs ETF
Proporción1.31%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.15%
Tema Heart & Health ETF
Proporción1.02%
SPDR S&P Biotech ETF
Proporción0.56%
WisdomTree BioRevolution Fund
Proporción0.45%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.44%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
